OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in antibiotics
2023;2

Repurposing Inhibitors of Phosphoinositide 3-kinase as Adjuvant Therapeutics for Bacterial Infections.

Renee Fleeman
Author Information
  1. Renee Fleeman: Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida. Orlando, FL 32837. ORCID
PMID: 38983593 DOI: 10.3389/frabi.2023.1135485

Abstract

The rise in antimicrobial resistance and the decline in new antibiotics has created a great need for novel approaches to treat drug resistant bacterial infections. Increasing the burden of antimicrobial resistance, bacterial virulence factors allow for survival within the host, where they can evade host killing and antimicrobial therapy within their intracellular niches. Repurposing host directed therapeutics has great potential for adjuvants to allow for more effective bacterial killing by the host and antimicrobials. To this end, phosphoinositide 3-kinase inhibitors are FDA approved for cancer therapy, but also have potential to eliminate intracellular survival of pathogens. This review describes the PI3K pathway and its potential as an adjuvant target to treat bacterial infections more effectively.

References

  1. Int J Biochem Mol Biol. 2011;2(2):168-182 [PMID: 21968800]
  2. Trends Mol Med. 2016 Dec;22(12):1060-1076 [PMID: 27866924]
  3. Acc Chem Res. 2021 Feb 16;54(4):917-929 [PMID: 33512995]
  4. FEMS Microbiol Lett. 2005 Feb 1;243(1):265-70 [PMID: 15668028]
  5. Clin Microbiol Rev. 2011 Jan;24(1):71-109 [PMID: 21233508]
  6. PLoS Pathog. 2010 Jun 24;6(6):e1000964 [PMID: 20585570]
  7. Genes Dev. 2012 Jul 15;26(14):1573-86 [PMID: 22802530]
  8. Nat Cancer. 2021 Jun;2(6):587-597 [PMID: 35118422]
  9. Front Microbiol. 2020 Sep 18;11:553962 [PMID: 33042061]
  10. Blood. 2014 Jan 9;123(2):239-48 [PMID: 24191150]
  11. J Cell Sci. 2014 Mar 1;127(Pt 5):923-8 [PMID: 24587488]
  12. Microbiol Mol Biol Rev. 2016 Mar 30;80(2):411-27 [PMID: 27030552]
  13. Microbiol Immunol. 2011 Jul;55(7):459-71 [PMID: 21707736]
  14. Trop Biomed. 2020 Jun 1;37(2):303-317 [PMID: 33612800]
  15. Cell Host Microbe. 2018 Aug 8;24(2):285-295.e8 [PMID: 30057173]
  16. Intensive Care Med. 2020 Aug;46(8):1552-1562 [PMID: 32572531]
  17. Proc Natl Acad Sci U S A. 1984 May;81(9):2728-32 [PMID: 6326140]
  18. FEMS Microbiol Lett. 2014 Dec;361(1):1-7 [PMID: 25283734]
  19. Am J Hematol. 2019 Dec;94(12):1325-1334 [PMID: 31490009]
  20. Chem Sci. 2020 May 19;11(23):5855-5865 [PMID: 32953006]
  21. Virulence. 2018;9(1):1390-1402 [PMID: 30103648]
  22. Nat Commun. 2019 Jan 14;10(1):197 [PMID: 30643129]
  23. Sci Rep. 2016 Mar 17;6:23277 [PMID: 26983806]
  24. Cell Rep. 2022 Aug 9;40(6):111167 [PMID: 35947948]
  25. PLoS Pathog. 2015 Mar 05;11(3):e1004644 [PMID: 25742647]
  26. Infect Immun. 2011 Nov;79(11):4569-77 [PMID: 21844240]
  27. J Biol Chem. 2000 Nov 24;275(47):36769-74 [PMID: 10973983]
  28. Cell. 1989 Apr 7;57(1):167-75 [PMID: 2467744]
  29. Mol Cancer. 2019 Feb 19;18(1):26 [PMID: 30782187]
  30. Lancet Infect Dis. 2016 Apr;16(4):e47-63 [PMID: 27036359]
  31. Immunobiology. 2013 Mar;218(3):325-37 [PMID: 22795971]
  32. Front Cell Infect Microbiol. 2016 May 17;6:52 [PMID: 27242970]
  33. Pathogens. 2020 Dec 10;9(12): [PMID: 33321710]
  34. Int J Mol Sci. 2021 Mar 27;22(7): [PMID: 33801659]
  35. FEBS J. 2021 Dec;288(24):7025-7042 [PMID: 33387369]
  36. Virulence. 2019 Dec;10(1):448-459 [PMID: 30322337]
  37. Microbiol Spectr. 2016 Jun;4(3): [PMID: 27337444]
  38. Expert Rev Clin Pharmacol. 2020 Aug;13(8):813-823 [PMID: 32576028]
  39. PLoS One. 2010 Jul 20;5(7):e11665 [PMID: 20652027]
  40. J Physiol Sci. 2019 Mar;69(2):263-280 [PMID: 30374841]
  41. J Biol Chem. 2003 Apr 18;278(16):14037-45 [PMID: 12571236]
  42. Front Immunol. 2021 Feb 25;12:636078 [PMID: 33717183]
  43. Front Microbiol. 2011 Aug 22;2:170 [PMID: 22007185]
  44. Pathogens. 2021 Sep 11;10(9): [PMID: 34578204]
  45. Mol Cell. 2018 Jul 19;71(2):343-351.e4 [PMID: 30029007]
  46. Cell Microbiol. 2002 Aug;4(8):503-14 [PMID: 12174085]
  47. Traffic. 2017 Nov;18(11):733-746 [PMID: 28799243]
  48. Nat Rev Drug Discov. 2018 Jan;17(1):35-56 [PMID: 28935918]
  49. J Cell Biol. 2011 Dec 26;195(7):1083-92 [PMID: 22123833]
  50. Cell Microbiol. 2015 Nov;17(11):1537-60 [PMID: 26045209]
  51. Expert Rev Anti Infect Ther. 2015 Feb;13(2):141-4 [PMID: 25413334]
  52. Nat Immunol. 2003 Apr;4(4):313-9 [PMID: 12660731]
  53. Clin Microbiol Rev. 2020 May 13;33(3): [PMID: 32404435]
  54. mBio. 2018 Jan 30;9(1): [PMID: 29382729]
  55. J Cell Sci. 2010 Dec 15;123(Pt 24):4240-50 [PMID: 21081650]
  56. Annu Rev Immunol. 2013;31:675-704 [PMID: 23330955]
  57. Trends Microbiol. 2022 Aug;30(8):736-748 [PMID: 35168833]
  58. Commun Integr Biol. 2013 Mar 1;6(2):e23360 [PMID: 23749323]
  59. Lab Invest. 2007 Jan;87(1):3-9 [PMID: 17146447]
  60. J Exp Med. 2003 Aug 18;198(4):653-9 [PMID: 12925680]
  61. Infect Immun. 1997 Jul;65(7):2950-8 [PMID: 9199471]
  62. Immunol Rev. 2021 May;301(1):62-83 [PMID: 33565103]
  63. J Infect Dis. 2008 Jun 1;197(11):1537-47 [PMID: 18419546]
  64. Tumori. 2023 Apr;109(2):244-248 [PMID: 35311394]
  65. Nature. 1985 May 16-22;315(6016):239-42 [PMID: 2987699]
  66. Cell. 2017 Aug 10;170(4):605-635 [PMID: 28802037]
  67. Cell Signal. 2014 May;26(5):942-50 [PMID: 24462705]
  68. Tuberculosis (Edinb). 2007 May;87(3):248-55 [PMID: 17258938]
  69. Nat Commun. 2015 Sep 21;6:8283 [PMID: 26387534]
  70. Crit Rev Microbiol. 2019 May;45(3):301-314 [PMID: 30985240]
  71. Br J Pharmacol. 2017 Jul;174(14):2225-2236 [PMID: 27925153]
  72. Int J Mol Sci. 2018 Dec 18;19(12): [PMID: 30567315]
  73. Mol Biol Cell. 2004 Feb;15(2):751-60 [PMID: 14617817]
  74. Cold Spring Harb Perspect Med. 2013 Apr 01;3(4):a010314 [PMID: 23545572]
  75. Oncogene. 2006 Mar 16;25(12):1743-52 [PMID: 16288223]
  76. Proc Natl Acad Sci U S A. 1984 Apr;81(7):2117-21 [PMID: 6326105]
  77. J Immunol. 2020 Dec 15;205(12):3237-3245 [PMID: 33288538]
  78. Nat Rev Drug Discov. 2014 Mar;13(3):162-4 [PMID: 24549135]
  79. Crit Care. 2002 Dec;6 Suppl 3:S1-18 [PMID: 12720570]
  80. Trends Microbiol. 2016 Nov;24(11):862-871 [PMID: 27430191]
  81. Front Immunol. 2014 Oct 07;5:481 [PMID: 25339955]
  82. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4033-8 [PMID: 15753315]
  83. Curr Oncol Rep. 2010 Mar;12(2):87-94 [PMID: 20425592]
  84. PLoS One. 2013 Aug 22;8(8):e71015 [PMID: 23990921]
  85. Clin Transl Med. 2012 Oct 13;1(1):24 [PMID: 23369170]
  86. ACS Infect Dis. 2019 Oct 11;5(10):1764-1771 [PMID: 31434474]
  87. Nat Rev Drug Discov. 2021 Oct;20(10):741-769 [PMID: 34127844]
  88. Theranostics. 2021 Mar 4;11(10):4910-4928 [PMID: 33754035]
  89. Trends Cell Biol. 2019 Apr;29(4):339-359 [PMID: 30691999]
  90. Nat Rev Microbiol. 2010 Sep;8(9):668-74 [PMID: 20676146]
  91. FEMS Microbiol Rev. 2019 Mar 1;43(2):123-144 [PMID: 30452654]
  92. Mediators Inflamm. 2018 Apr 11;2018:4065362 [PMID: 29849488]
  93. Cancers (Basel). 2021 Aug 05;13(16): [PMID: 34439105]
  94. Signal Transduct Target Ther. 2021 Dec 16;6(1):425 [PMID: 34916492]
  95. Nat Rev Microbiol. 2019 Apr;17(4):203-218 [PMID: 30737488]
  96. Blood. 2015 Aug 27;126(9):1128-37 [PMID: 26109204]
  97. Bone Joint Res. 2020 May 16;9(2):49-59 [PMID: 32435455]
  98. Infect Dis Clin North Am. 2009 Mar;23(1):17-34 [PMID: 19135914]
  99. Biochim Biophys Acta. 2015 Jun;1851(6):882-97 [PMID: 25514767]
  100. Front Microbiol. 2012 Feb 29;3:71 [PMID: 22393329]
  101. mSphere. 2017 Jul 19;2(4): [PMID: 28744480]
  102. Clin Cancer Res. 2015 Apr 1;21(7):1537-42 [PMID: 25670221]
  103. Biomolecules. 2019 Aug 30;9(9): [PMID: 31480354]
  104. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2241-6 [PMID: 20133867]
  105. Trends Microbiol. 2009 Feb;17(2):54-8 [PMID: 19162480]
  106. Lancet Oncol. 2022 May;23(5):563-566 [PMID: 35429996]
  107. Front Microbiol. 2020 Apr 23;11:563 [PMID: 32390959]
  108. J Leukoc Biol. 2012 Sep;92(3):553-66 [PMID: 22569897]
  109. FEMS Microbiol Rev. 2018 Jul 1;42(4):425-447 [PMID: 29596635]
  110. J Med Chem. 2012 Jun 14;55(11):5467-82 [PMID: 22548342]
  111. Semin Immunopathol. 2016 Mar;38(2):167-83 [PMID: 26510950]
  112. Nat Rev Cancer. 2020 Feb;20(2):74-88 [PMID: 31686003]
  113. Biomedicines. 2022 Jul 27;10(8): [PMID: 36009351]
  114. Nature. 1988 Apr 14;332(6165):644-6 [PMID: 2833705]
  115. Inflammation. 2019 Oct;42(5):1741-1753 [PMID: 31267272]
  116. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1963-9 [PMID: 15319270]
  117. Cell Mol Immunol. 2016 Nov;13(6):729-746 [PMID: 26166760]
  118. Nat Rev Immunol. 2023 Feb;23(2):121-133 [PMID: 35672482]
  119. Virulence. 2017 Nov 17;8(8):1761-1775 [PMID: 28762868]
  120. J Cell Biol. 2008 May 19;181(4):655-66 [PMID: 18474623]
  121. J Family Community Med. 2010 Sep;17(3):117-20 [PMID: 21359021]
  122. J Pathog. 2019 Aug 6;2019:8604958 [PMID: 31467721]
  123. Front Immunol. 2019 Nov 01;10:2583 [PMID: 31736982]
  124. Cell Host Microbe. 2017 Nov 8;22(5):667-677.e5 [PMID: 29120744]
  125. J Physiol Sci. 2020 Mar 19;70(1):18 [PMID: 32192434]
  126. Elife. 2020 Jun 30;9: [PMID: 32602837]
  127. Cancer Cell. 2017 Oct 9;32(4):444-459.e7 [PMID: 29017056]
  128. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2003-8 [PMID: 22308354]
  129. J Cell Biol. 2001 Oct 1;155(1):15-7 [PMID: 11581282]
  130. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3915-3920 [PMID: 28348208]

Grants

  1. K99 AI163295/NIAID NIH HHS
Journal Article

Word Cloud

Created with Highcharts 10.0.0bacterialhostantimicrobialpotentialresistancegreattreatinfectionsallowsurvivalwithinkillingtherapyintracellularRepurposing3-kinaserisedeclinenewantibioticscreatedneednovelapproachesdrugresistantIncreasingburdenvirulencefactorscanevadenichesdirectedtherapeuticsadjuvantseffectiveantimicrobialsendphosphoinositideinhibitorsFDAapprovedcanceralsoeliminatepathogensreviewdescribesPI3KpathwayadjuvanttargeteffectivelyInhibitorsPhosphoinositideAdjuvantTherapeuticsBacterialInfections

Similar Articles

Cited By